Roles of AGEs as exacerbation factor in pathogenesis of tissue remodeling and the development of novel targeted therapy
Project/Area Number |
15K08605
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | Shujitsu University |
Principal Investigator |
MORI Shuji 就実大学, 薬学部, 教授 (50220009)
|
Co-Investigator(Kenkyū-buntansha) |
豊村 隆男 就実大学, 薬学部, 講師 (40425137)
渡邊 政博 就実大学, 薬学部, 助教 (10758246)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | 炎症 / 組織リモデリング / サイトカイン / 分子標的 |
Outline of Final Research Achievements |
We screened the binding factor which can interact with HMGB1 by ProtoArray analysis, and studied the pathophysiological roles of its interaction. As the result, we found that TWEAK can interact with HMGB1 with high affinity. TWEAK induced the enhancement of IL-8 mRNA expression in endothelial cells. AGEs specifically bind to TWEAK, and inhibited some inflammatory activities including TWEAK-induced IL-8 mRNA expression. These findings indicated the importance of TWEAK-AGEs interaction as novel therapeutic target molecule in the inflammatory diseases.
|
Report
(4 results)
Research Products
(12 results)